Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PLC Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Firm's Heart Laser carbon dioxide transmyocardial revascularization laser reduces average angina class to 1.5 from an average preoperative class of 3.8 after three years follow-up according to a study presented Nov. 9 at the American Heart Association conference in Dallas by Keith Horvath, MD, Northwest University Medical Center. Of the 70 patients followed in the 8-hospital study, 23% reported having no angina and 58% were in angina class 1 or 2 after three years. Functional improvement on exercise treadmill times increased by 28% after 24 months and survival rates at one and three years were 84% and 78% respectively. The independent study represents the longest follow-up of TMR patients, PLC said

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel